FDA clears Stallion digital package
Stallion Technologies is planning its entry into the medical imaging market after receiving 510(k) clearance for a digital image processing package for dynamic x-ray modalities. Stallion began marketing its X-Sight package to medical imaging OEMs and
Stallion Technologies is planning its entry into the medical imaging market after receiving 510(k) clearance for a digital image processing package for dynamic x-ray modalities. Stallion began marketing its X-Sight package to medical imaging OEMs and major distributors after winning Food and Drug Administration clearance in January.
The main feature of X-Sight is its flexibility, according to Marshall Ma, general manager of the Liverpool, NY, company. The package supports a wide range of x-ray systems, including radiography-fluoroscopy, C-arms, angiography suites, and cardiac catheterization labs. X-Sight also is available in configurations that support high-end techniques such as digital subtraction angiography and biplane cardiac cath. In its basic configuration, X-Sight is capable of resolutions of up to 2048 x 2048 in 10 bits, with 12-bit real-time image processing functions. It also supports acquisition rates of up to 120 fps.
X-Sight supports digital acquisition technologies ranging from analog cameras to CCD-based systems, and the company is working on developing an interface to flat-panel digital sensors in development. Stallion is an engineering services firm that has decided to branch out into medical imaging by developing the software used in X-Sight, Ma said.
What a New Mammography Study Reveals About BMI, Race, Ethnicity and Advanced Breast Cancer Risk
December 8th 2023In a new study examining population attributable risk proportions (PARPs) based on data from over three million screening mammography exams, researchers found that postmenopausal Black women had the highest BMI-related PARP and premenopausal Asian and Pacific Islander women had the highest breast density-related PARP for advanced breast cancer.
Study: Contrast-Enhanced Mammography Changes Surgical Plan in 22.5 Percent of Breast Cancer Cases
December 7th 2023Contrast-enhanced mammography detected additional lesions in 43 percent of patients and led to additional biopsies in 18.2 percent of patients, over half of whom had malignant lesions, according to a study of over 500 women presented at the recent Radiological Society of North America (RSNA) conference.
